AR082314A1 - Una composicion farmaceutica de combinacion para el tratamiento de vertigo, cinetosis y distonia vegetativa vascular - Google Patents
Una composicion farmaceutica de combinacion para el tratamiento de vertigo, cinetosis y distonia vegetativa vascularInfo
- Publication number
- AR082314A1 AR082314A1 ARP110102644A ARP110102644A AR082314A1 AR 082314 A1 AR082314 A1 AR 082314A1 AR P110102644 A ARP110102644 A AR P110102644A AR P110102644 A ARP110102644 A AR P110102644A AR 082314 A1 AR082314 A1 AR 082314A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibody
- activated form
- enhanced activated
- pharmaceutical composition
- vascular
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 230000002792 vascular Effects 0.000 title abstract 2
- 208000012886 Vertigo Diseases 0.000 title 1
- 231100000889 vertigo Toxicity 0.000 title 1
- 210000004556 brain Anatomy 0.000 abstract 6
- 239000008194 pharmaceutical composition Substances 0.000 abstract 6
- 102000004169 proteins and genes Human genes 0.000 abstract 6
- 108090000623 proteins and genes Proteins 0.000 abstract 6
- 102000008299 Nitric Oxide Synthase Human genes 0.000 abstract 4
- 108010021487 Nitric Oxide Synthase Proteins 0.000 abstract 4
- 239000012895 dilution Substances 0.000 abstract 4
- 238000010790 dilution Methods 0.000 abstract 4
- 230000003511 endothelial effect Effects 0.000 abstract 4
- 230000001632 homeopathic effect Effects 0.000 abstract 4
- 239000007787 solid Substances 0.000 abstract 4
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Otolaryngology (AREA)
- Diabetes (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2010130356/15A RU2542453C2 (ru) | 2010-07-21 | 2010-07-21 | Лекарственное средство и способ лечения вегето-сосудистой дистонии, синдрома головокружения различного генеза и кинетозов |
| RU2010130353/15A RU2542445C2 (ru) | 2010-07-21 | 2010-07-21 | Лекарственное средство для лечения болезни альцгеймера и способ лечения болезни альцгеймера |
| RU2011127058/15A RU2536232C2 (ru) | 2011-07-01 | 2011-07-01 | Лекарственное средство для лечения болезни альцгеймера и способ лечения болезни альцгеймера |
| RU2011127052/15A RU2503462C2 (ru) | 2011-07-01 | 2011-07-01 | Способ лечения головокружения различного генеза, кинетозов и вегето-сосудистой дистонии (варианты) и лекарственное средство |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR082314A1 true AR082314A1 (es) | 2012-11-28 |
Family
ID=44899157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110102644A AR082314A1 (es) | 2010-07-21 | 2011-07-21 | Una composicion farmaceutica de combinacion para el tratamiento de vertigo, cinetosis y distonia vegetativa vascular |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20130058981A1 (OSRAM) |
| EP (1) | EP2596018A2 (OSRAM) |
| JP (2) | JP2013536174A (OSRAM) |
| KR (1) | KR20130102542A (OSRAM) |
| CN (1) | CN103124741A (OSRAM) |
| AR (1) | AR082314A1 (OSRAM) |
| AU (1) | AU2011281248B2 (OSRAM) |
| BR (1) | BR112013001296A2 (OSRAM) |
| CA (1) | CA2805985A1 (OSRAM) |
| CL (1) | CL2013000201A1 (OSRAM) |
| DE (1) | DE112011102397T5 (OSRAM) |
| EA (1) | EA029998B1 (OSRAM) |
| ES (1) | ES2446643R1 (OSRAM) |
| FR (1) | FR2962910A1 (OSRAM) |
| GB (1) | GB2496342B (OSRAM) |
| IL (1) | IL224336A (OSRAM) |
| IT (1) | ITTO20110630A1 (OSRAM) |
| MX (1) | MX355371B (OSRAM) |
| NZ (1) | NZ606988A (OSRAM) |
| PE (1) | PE20131065A1 (OSRAM) |
| PH (1) | PH12013500141A1 (OSRAM) |
| SG (2) | SG10201505676RA (OSRAM) |
| WO (1) | WO2012010974A2 (OSRAM) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2181297C2 (ru) | 2000-06-20 | 2002-04-20 | Эпштейн Олег Ильич | Способ лечения патологического синдрома и лекарственное средство |
| UA76638C2 (en) | 2002-08-02 | 2006-08-15 | Oleh Illich Epshtein | Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon |
| RU2309732C1 (ru) * | 2006-03-13 | 2007-11-10 | Олег Ильич Эпштейн | Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата |
| WO2012007845A2 (en) * | 2010-07-15 | 2012-01-19 | Oleg Iliich Epshtein | A method of increasing the effect of an activated-potentiated form of an antibody |
| ES2542042R1 (es) | 2010-07-15 | 2015-10-06 | Oleg Iliich Epshtein | Composiciones farmacéuticas y uso para preparar un medicamento destinado al tratamiento de la obesidad, los trastornos metabólicos relacionados y la adicción a sustancias psicoactivas |
| US8637034B2 (en) | 2010-07-15 | 2014-01-28 | Oleg I. Epshtein | Pharmaceutical compositions comprising activated-potentiated antibodies to interferon-gamma and S100 protein |
| EP2595658A2 (en) * | 2010-07-21 | 2013-05-29 | Oleg Iliich Epshtein | A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders |
| ES2425315R1 (es) * | 2010-07-21 | 2014-09-08 | Oleg Iliich Epshtein | Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento sintomático de una enfermedad o afección respiratoria |
| CN103119061A (zh) | 2010-07-21 | 2013-05-22 | 奥列格·伊里奇·爱泼斯坦 | 治疗注意力不足过动症的方法 |
| GB2496801B (en) * | 2010-07-21 | 2018-04-11 | Iliich Epshtein Oleg | A method of treating alzheimer's disease |
| JP2013537532A (ja) * | 2010-08-06 | 2013-10-03 | イリイチ・エプシテイン オレグ | 感染性疾患を治療及び予防する組み合わせ医薬組成物及び方法 |
| RU2013111962A (ru) | 2013-03-18 | 2014-09-27 | Олег Ильич Эпштейн | Способ определения выраженности модифицирующей активности, ассоциированной с носителем |
| RU2013111961A (ru) | 2013-03-18 | 2014-09-27 | Олег Ильич Эпштейн | Способ определения выраженности модифицирующей активности, ассоциированной с носителем |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4311897A (en) | 1979-08-28 | 1982-01-19 | Union Carbide Corporation | Plasma arc torch and nozzle assembly |
| RU2113230C1 (ru) | 1996-04-03 | 1998-06-20 | Ильчиков Михаил Захарович | Седативное лекарственное средство "авиаморе" |
| US6150500A (en) * | 1996-07-12 | 2000-11-21 | Salerno; John C. | Activators of endothelial nitric oxide synthase |
| US5849528A (en) * | 1997-08-21 | 1998-12-15 | Incyte Pharmaceuticals, Inc.. | Polynucleotides encoding a human S100 protein |
| RU2156621C1 (ru) | 1999-03-04 | 2000-09-27 | Эпштейн Олег Ильич | Нейротропное лекарственное средство |
| RU2181297C2 (ru) * | 2000-06-20 | 2002-04-20 | Эпштейн Олег Ильич | Способ лечения патологического синдрома и лекарственное средство |
| US20030087250A1 (en) * | 2001-03-14 | 2003-05-08 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer |
| RU2201255C1 (ru) * | 2001-12-26 | 2003-03-27 | Эпштейн Олег Ильич | Лекарственное средство и способ регуляции сосудистого тонуса |
| UA76638C2 (en) * | 2002-08-02 | 2006-08-15 | Oleh Illich Epshtein | Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon |
| UA76639C2 (uk) * | 2002-08-02 | 2006-08-15 | Олєг Ільіч Епштєйн | Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій |
| UA76641C2 (uk) | 2002-08-02 | 2006-08-15 | Олєг Ільіч Епштєйн | Гомеопатичний лікарський засіб та спосіб лікування захворювань передміхурової залози |
| AU2003295328A1 (en) * | 2002-10-02 | 2004-04-23 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| CN101107003B (zh) | 2003-03-14 | 2012-08-08 | 营养学研究有限公司 | 用于治疗疼痛和/或炎症的顺势疗法的配剂 |
| WO2012007845A2 (en) * | 2010-07-15 | 2012-01-19 | Oleg Iliich Epshtein | A method of increasing the effect of an activated-potentiated form of an antibody |
| ES2542042R1 (es) * | 2010-07-15 | 2015-10-06 | Oleg Iliich Epshtein | Composiciones farmacéuticas y uso para preparar un medicamento destinado al tratamiento de la obesidad, los trastornos metabólicos relacionados y la adicción a sustancias psicoactivas |
| US8637034B2 (en) * | 2010-07-15 | 2014-01-28 | Oleg I. Epshtein | Pharmaceutical compositions comprising activated-potentiated antibodies to interferon-gamma and S100 protein |
| ES2425315R1 (es) * | 2010-07-21 | 2014-09-08 | Oleg Iliich Epshtein | Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento sintomático de una enfermedad o afección respiratoria |
| CN103119061A (zh) * | 2010-07-21 | 2013-05-22 | 奥列格·伊里奇·爱泼斯坦 | 治疗注意力不足过动症的方法 |
| EP2595658A2 (en) * | 2010-07-21 | 2013-05-29 | Oleg Iliich Epshtein | A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders |
| EP2596020A2 (en) * | 2010-07-21 | 2013-05-29 | Oleg Iliich Epshtein | Method of treatment of organic diseases of nervous system, psychoorganic syndrome and encephalopathy |
| GB2496801B (en) * | 2010-07-21 | 2018-04-11 | Iliich Epshtein Oleg | A method of treating alzheimer's disease |
-
2011
- 2011-07-15 KR KR1020137004331A patent/KR20130102542A/ko not_active Ceased
- 2011-07-15 CA CA2805985A patent/CA2805985A1/en not_active Abandoned
- 2011-07-15 AU AU2011281248A patent/AU2011281248B2/en not_active Ceased
- 2011-07-15 BR BR112013001296A patent/BR112013001296A2/pt not_active IP Right Cessation
- 2011-07-15 PE PE2013000111A patent/PE20131065A1/es not_active Application Discontinuation
- 2011-07-15 MX MX2013000805A patent/MX355371B/es active IP Right Grant
- 2011-07-15 ES ES201390010A patent/ES2446643R1/es active Pending
- 2011-07-15 NZ NZ606988A patent/NZ606988A/en not_active IP Right Cessation
- 2011-07-15 WO PCT/IB2011/002378 patent/WO2012010974A2/en not_active Ceased
- 2011-07-15 IT IT000630A patent/ITTO20110630A1/it unknown
- 2011-07-15 US US13/135,887 patent/US20130058981A1/en not_active Abandoned
- 2011-07-15 DE DE112011102397T patent/DE112011102397T5/de not_active Withdrawn
- 2011-07-15 GB GB1302925.1A patent/GB2496342B/en not_active Expired - Fee Related
- 2011-07-15 JP JP2013520240A patent/JP2013536174A/ja active Pending
- 2011-07-15 CN CN2011800454598A patent/CN103124741A/zh active Pending
- 2011-07-15 EA EA201300127A patent/EA029998B1/ru not_active IP Right Cessation
- 2011-07-15 SG SG10201505676RA patent/SG10201505676RA/en unknown
- 2011-07-15 SG SG2013004809A patent/SG187160A1/en unknown
- 2011-07-15 EP EP11773316.2A patent/EP2596018A2/en not_active Ceased
- 2011-07-15 PH PH1/2013/500141A patent/PH12013500141A1/en unknown
- 2011-07-15 FR FR1156477A patent/FR2962910A1/fr not_active Withdrawn
- 2011-07-21 AR ARP110102644A patent/AR082314A1/es unknown
-
2013
- 2013-01-20 IL IL224336A patent/IL224336A/en active IP Right Grant
- 2013-01-21 CL CL2013000201A patent/CL2013000201A1/es unknown
-
2016
- 2016-07-01 JP JP2016131718A patent/JP2016199571A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PE20131065A1 (es) | 2013-09-23 |
| DE112011102397T5 (de) | 2013-05-08 |
| CN103124741A (zh) | 2013-05-29 |
| CA2805985A1 (en) | 2012-01-26 |
| SG10201505676RA (en) | 2015-08-28 |
| CL2013000201A1 (es) | 2015-01-23 |
| AU2011281248A1 (en) | 2013-03-14 |
| ES2446643A2 (es) | 2014-03-10 |
| WO2012010974A8 (en) | 2013-04-25 |
| US20130058981A1 (en) | 2013-03-07 |
| NZ606988A (en) | 2015-08-28 |
| MX2013000805A (es) | 2013-10-28 |
| GB2496342A (en) | 2013-05-08 |
| SG187160A1 (en) | 2013-02-28 |
| IL224336A (en) | 2017-06-29 |
| EA029998B1 (ru) | 2018-06-29 |
| MX355371B (es) | 2018-04-17 |
| EA201300127A1 (ru) | 2013-12-30 |
| GB2496342B (en) | 2017-12-06 |
| PH12013500141A1 (en) | 2013-03-11 |
| KR20130102542A (ko) | 2013-09-17 |
| EP2596018A2 (en) | 2013-05-29 |
| ITTO20110630A1 (it) | 2012-01-22 |
| WO2012010974A3 (en) | 2012-04-19 |
| FR2962910A1 (fr) | 2012-01-27 |
| JP2013536174A (ja) | 2013-09-19 |
| JP2016199571A (ja) | 2016-12-01 |
| AU2011281248B2 (en) | 2017-02-02 |
| WO2012010974A2 (en) | 2012-01-26 |
| ES2446643R1 (es) | 2015-03-06 |
| BR112013001296A2 (pt) | 2017-12-19 |
| GB201302925D0 (en) | 2013-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR082314A1 (es) | Una composicion farmaceutica de combinacion para el tratamiento de vertigo, cinetosis y distonia vegetativa vascular | |
| AR082246A1 (es) | Composicion farmaceutica de anticuerpo a receptor cannabinoide humano | |
| AR118047A2 (es) | Anticuerpo aislado o fragmento del mismo, composición farmacéutica y molécula biespecífica | |
| ECSP13012436A (es) | ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS | |
| CO2018000211A2 (es) | Moléculas de anticuerpo que se unen a cd45 | |
| AR124676A2 (es) | Formulación farmacéutica que comprende una droga biofarmacéutica | |
| UA112416C2 (uk) | Антитіло до fap і способи його застосування | |
| AR076195A1 (es) | Anticuerpos biespecificos anti-erbb-1/anti-c-met | |
| MX362456B (es) | Anticuerpos y vacunas para utilizarse en el tratamiento de canceres por ror1 y para inhibir la metastasis. | |
| EA201491644A1 (ru) | Фармацевтические композиции | |
| CL2011002831A1 (es) | Anticuerpo humanizado especifico de la forma protofibrilar del peptido a-beta; uso de dicho anticuerpo para tratar transtornos neurodegenerativos; composicion farmaceutica; celula que produce dichos anticuerpos; y procedimientos de preparacion de dicho anticuerpo. | |
| MX2021011167A (es) | Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso. | |
| CL2012003283A1 (es) | Anticuerpo humano aislado o un fragmento de union al antigeno del mismo porque se une o bloquea la actividad biológica de gdf-8 humano maduro de tipo natural; composicion farmacéutica que comprende dicho anticuerpo o el fragmento de unión al antígeno; uso del anticuerpo para tratar una enfermedad o trastorno tratable mediante la inhibición de la actividad de gdf-8. | |
| BR112018072681A2 (pt) | anticorpos anti-il-1r3 humanizados | |
| EA201890315A1 (ru) | Молекулы антител, связывающие cd22 | |
| CL2018000107A1 (es) | Moléculas de anticuerpo que se unen a cd79 | |
| AR082518A1 (es) | Anticuerpos contra il-18r1 y usos de los mismos | |
| PE20140673A1 (es) | Nuevos moduladores y metodos para su uso | |
| AR101846A1 (es) | Anticuerpos anti-cll-1 e inmunoconjugados | |
| AR091069A1 (es) | Proteinas de union a antigeno dirigidas contra el receptor st2 | |
| PE20161032A1 (es) | Anticuerpos anti-tau(ps422) humanizados y metodos de utilizacion | |
| EA201071300A1 (ru) | Антитела к cxcr4 | |
| EA201391136A1 (ru) | Лиофилизированные составы | |
| EA201990298A1 (ru) | Способы и композиции для лечения рака | |
| UA112755C2 (uk) | Метод лікування синдрому дефіциту уваги і гіперактивності |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |